STOCK TITAN

Boatim Inc - BTIM STOCK NEWS

Welcome to our dedicated news page for Boatim (Ticker: BTIM), a resource for investors and traders seeking the latest updates and insights on Boatim.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Boatim's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Boatim's position in the market.

Rhea-AI Summary
Lineage Cell Therapeutics announces issuance of U.S. Patent for Large Scale Production of Retinal Pigment Epithelial Cells
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Lineage Cell Therapeutics presents positive results of Phase 1/2a study of OpRegen at EURETINA Congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Lineage Cell Therapeutics CEO to present at Cantor Fitzgerald 2023 Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary
Lineage Cell Therapeutics announces positive results from Phase 1/2a study of RG6501 (OpRegen) in treating age-related macular degeneration (AMD)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Lineage Cell Therapeutics' Senior VP to present at ISRT Network Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Lineage Cell Therapeutics announced initiation of development activities for a novel hypoimmune induced pluripotent stem cell line under its agreement with Eterna Therapeutics. The company has finalized specific gene edits for the initial cell lines, including targeted deletion and insertion of genes to reduce immunogenicity and prevent rejection. Lineage expects these edits to expand the cell lines' utility and differentiate them from competitors' products. The collaboration aims to capitalize on cell engineering and editing technologies to create superior cell transplant therapies. Eterna will conduct gene-editing activities and provide materials to Lineage under the agreement. Lineage has an option to obtain an exclusive license for the gene-edited cell lines for CNS diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership
Rhea-AI Summary
Lineage Cell Therapeutics, Inc. CEO to present at Baird's 2023 Global Healthcare Conference and H.C. Wainwright 25th Annual Global Investment Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
Rhea-AI Summary
Lineage Cell Therapeutics and Cancer Research UK announce positive results from a clinical study of VAC2 in advanced non-small cell lung cancer (NSCLC). Five out of eight patients treated had a best response of stable disease, and three demonstrated progressive disease. No serious adverse events were reported. Three patients reached the 2-year survival endpoint. Further analyses are being conducted.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Boatim Inc

NYSE:BTIM

BTIM Rankings

BTIM Stock Data

60
29.01M
54.22%
Internet Content & Information
Communication Services
Link
United States
Miami

About BTIM

welcome on board! boatim is an international online marketplace for boats & yachts.